These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31727164)

  • 1. Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation.
    da Silva MRR; Dos Santos JBR; Almeida AM; Alvares-Teodoro J; Kakehasi AM; Acurcio FA
    Adv Rheumatol; 2019 Nov; 59(1):48. PubMed ID: 31727164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
    Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
    Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study.
    Mease PJ; Liu C; Siegel E; Richmond H; Wu M; Chen L; Douglas K; Lockshin B
    Am J Clin Dermatol; 2019 Dec; 20(6):873-880. PubMed ID: 31612380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study.
    Souza AF; Silva MRD; Santos JBD; Almeida AM; Acurcio FA; Alvares-Teodoro J
    Pharm Pract (Granada); 2021; 19(2):2312. PubMed ID: 34221199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations.
    da Silva MRR; Dos Santos JBR; Almeida AM; Guerra Júnior AA; Alvares Teodoro J; Acurcio FA
    Expert Rev Clin Immunol; 2019 Aug; 15(8):879-887. PubMed ID: 31192746
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
    Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
    Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of pharmaceutical care in patients with psoriatic arthritis using statutory health insurance data.
    Sondermann W; Ventzke J; Matusiewicz D; Körber A
    J Dtsch Dermatol Ges; 2018 Mar; 16(3):285-294. PubMed ID: 29537175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan.
    Li TH; Liao HT; Huang YF; Shen YC; Chiu YC; Chen WS; Chen MH; Tsai CY; Chang DM
    J Formos Med Assoc; 2018 May; 117(5):404-412. PubMed ID: 28552625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of rheumatoid arthritis in the public health system in Santa Catarina, Brazil: a descriptive and temporal trend analysis from 1996 to 2009.
    Gomes RKS; Pires FA; Nobre MRC; Marchi MFS; Rickli JCK
    Rev Bras Reumatol Engl Ed; 2017; 57(3):204-209. PubMed ID: 28535891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
    Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
    Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
    Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
    Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
    Cummins E; Asseburg C; Punekar YS; Shore E; Morris J; Briggs A; Fenwick E
    Value Health; 2011 Jan; 14(1):15-23. PubMed ID: 21211482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.
    Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A;
    Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.